Impact of Platelet Rich Plasma Over Alternative Therapies in Patients With Lateral Epicondylitis
| Status: | Active, not recruiting |
|---|---|
| Conditions: | Orthopedic |
| Therapuetic Areas: | Orthopedics / Podiatry |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 1/3/2018 |
| Start Date: | January 2013 |
| End Date: | August 2018 |
Impact of Platelet Rich Plasma Over Alternative Therapies With Lateral Epicondylitis (IMPROVE): A Multicenter, Randomized Trial Comparing Autologous Whole Blood vs. Dry Needle Tendon Fenestration of Pain and Quality of Life in Patients With Lateral Epicondylitis.
This Pilot study is a Multicenter, Randomized Trial comparing autologous platelet rich plasma
(PRP) versus autologous whole blood versus dry needle tendon fenestration on pain and quality
of life in patients with lateral epicondylitis (tennis elbow). We want to find out if pain
and mobility are improved in people who receive an injection of PRP compared to a group of
people who receive an injection of whole blood, a group treated with dry needle tendon
fenestration and a group of people who receive no injection.
(PRP) versus autologous whole blood versus dry needle tendon fenestration on pain and quality
of life in patients with lateral epicondylitis (tennis elbow). We want to find out if pain
and mobility are improved in people who receive an injection of PRP compared to a group of
people who receive an injection of whole blood, a group treated with dry needle tendon
fenestration and a group of people who receive no injection.
Platelet rich plasma (PRP) deserves study because it is more expensive than the other
treatments. If we learn that PRP is better compared to the other treatments, it would justify
the high cost and growing industry associated with the procedure. If we find out that PRP is
not better compared to the other treatments, there is the potential to save the health care
system millions of dollars.
We hope to show that we can recruit eligible participants and and complete the treatment and
tests to answer the questions regarding the effectiveness of platelet rich plasma for
patients with tennis elbow.
treatments. If we learn that PRP is better compared to the other treatments, it would justify
the high cost and growing industry associated with the procedure. If we find out that PRP is
not better compared to the other treatments, there is the potential to save the health care
system millions of dollars.
We hope to show that we can recruit eligible participants and and complete the treatment and
tests to answer the questions regarding the effectiveness of platelet rich plasma for
patients with tennis elbow.
Inclusion Criteria:
- Age - 18 years or older
- Have diagnosis of lateral epicondylitis (tennis elbow)
- Symptoms lasting at least 3 months or longer
- Have pain on a scale of 1 to 10 at level 5
(1=no pain and 10=severe pain)
- Documented sonographic diagnosis of common extensor tendinosis based on tendon
thickening, areas of hypoechogenicity, and loss of the normal echotexture.
Exclusion Criteria:
- Acute symptom onset less than 2 months
- History of acute elbow trauma less than 1 week
- History of rheumatoid arthritis
- History of malignancy
- Pregnant
- Patients requiring anti-platelet medication for the treatment of heart attack, stroke,
or other medical condition
- Previous surgery for lateral epicondylitis
- Previous local injections, including steroids within the past 6 months
- Signs of other causes for lateral elbow pain (posterior interosseous nerve entrapment,
osteochondral lesion)
We found this trial at
2
sites
Ann Arbor, Michigan 48109
Principal Investigator: jon Jacobson, MD
Phone: 734-936-4365
Click here to add this to my saved trials
Click here to add this to my saved trials